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An extract of Urtica dioica L. 
mitigates obesity induced insulin 
resistance in mice skeletal muscle 
via protein phosphatase 2A (PP2A)
Diana N. Obanda1, David Ribnicky2, Yongmei Yu1, Jacqueline Stephens1 & William T. Cefalu1
The leaf extract of Urtica dioica L. (UT) has been reported to improve glucose homeostasis in vivo, but 
definitive studies on efficacy and mechanism of action are lacking. We investigated the effects of UT 
on obesity- induced insulin resistance in skeletal muscle. Male C57BL/6J mice were divided into three 
groups: low-fat diet (LFD), high-fat diet (HFD) and HFD supplemented with UT. Body weight, body 
composition, plasma glucose and plasma insulin were monitored. Skeletal muscle (gastrocnemius) 
was analyzed for insulin sensitivity, ceramide accumulation and the post translational modification 
and activity of protein phosphatase 2A (PP2A). PP2A is activated by ceramides and dephosphorylates 
Akt. C2C12 myotubes exposed to excess free fatty acids with or without UT were also evaluated for 
insulin signaling and modulation of PP2A. The HFD induced insulin resistance, increased fasting plasma 
glucose, enhanced ceramide accumulation and PP2A activity in skeletal muscle. Supplementation with 
UT improved plasma glucose homeostasis and enhanced skeletal muscle insulin sensitivity without 
affecting body weight and body composition. In myotubes, UT attenuated the ability of FFAs to 
induce insulin resistance and PP2A hyperactivity without affecting ceramide accumulation and PP2A 
expression. UT decreased PP2A activity through posttranslational modification that was accompanied 
by a reduction in Akt dephosphorylation.
Obesity induced insulin resistance is a key pathophysiologic feature of type 2 diabetes mellitus (T2DM). 
Progression of insulin resistance into overt T2DM can be prevented or delayed by timely intervention1,2. 
Treatment of subjects with insulin resistance is directed at increasing insulin sensitivity. Reduction in calorie 
intake and increase in physical activity are effective but difficult to maintain in the long-term. Therefore, conven-
tional medications that address insulin resistance are an option in clinical medicine3 and are a major focus for 
drug development.
Insulin resistance is induced by the accumulation of lipid metabolites from excess fat in insulin sensitive cells. 
Excess dietary carbohydrate not stored as glycogen or oxidized for energy is converted to fat by de novo lipogen-
esis4. Among the fatty acid derived metabolites, ceramides are most active in negatively regulating insulin sign-
aling5,6. The primary target of ceramides in the insulin signaling pathway is Akt whose activity state is regulated 
by serine/threonine phosphorylation5–7. Ceramides activate cytosolic protein phosphatase 2A (PP2A) a serine/
threonine phosphatase that dephosphorylates Akt leaving it inactivated and unable to mediate insulin stimulated 
glucose uptake and metabolism7. Thus, interventions that may modulate this pathway may be useful for treatment 
for insulin resistance.
Because some conventional medications marketed for insulin resistance have troublesome side effects8,9, there 
is increasing interest in natural complementary and alternative therapies from plants. Use of over the counter 
botanical agents is extensively practiced by a large number of patients. Plants have traditionally been a rich source 
of medicinal compounds for many indications. A number of botanicals have shown promise as therapies for 
insulin resistance and hyperglycemia. Among these is the extract of Urtica dioica L. (UT) or stinging nettle (fam-
ily Urticaceae) whose blood glucose lowering effect has been historically noted and supported by recent animal 
studies and in vitro studies10–13. However, the mechanism(s) that contribute to these positive systemic effects of 
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UT are largely unknown and bioactive components are not elucidated. Despite this paucity of data on efficacy and 
mechanism(s), UT dietary supplements are widely available in the United States. The acceptance and widespread 
use of botanical supplements by the general public justifies research in investigating their mechanisms of action. 
The overall objective of the current study was to examine the efficacy and mechanism(s) of action of UT as a die-
tary supplement for ameliorating diet induced insulin resistance in skeletal muscle.
In this study, we hypothesized that UT maintains insulin sensitivity through mechanisms that enhance Akt 
phosphorylation despite the accumulation of ceramides in skeletal muscle. Increased Akt phosphorylation can 
be achieved by either increase in the activities of kinases that phosphorylate it or by a decrease in activities of 
phosphatases that modulate its activity. Based on previous reports that have demonstrated that PP2A inhibition 
with okadaic acid or a neutralizing antibody increased Akt activity14–17, we determined the effect of UT on the 
activity of PP2A. Our observations from two model systems that include in vitro and in vivo studies demonstrate 
that supplementation with UT attenuates lipid induced PP2A hyperactivity and enhances insulin sensitivity and 
insulin stimulated glucose metabolism in skeletal muscle. These studies strongly suggest that UT has metaboli-
cally beneficial effects in skeletal muscle and indicate its potential as a botanical supplement for metabolic disease 
states such as insulin resistance.
Materials and Methods
Source and preparation and of plant extract. Urtica dioica L. (UT) was harvested as the total herb 
above the root mass and a voucher specimen was produced by the Botanical Research Center and deposited in the 
Chrysler Herbarium at Rutgers University. The plant was harvested in New Jersey. Geographic coordinates of the 
botanical collection site are 40°36′03.9“N 74°40'30.1“W. The freeze-dried plant was stored at −20 °C. For extrac-
tion, 3 kg of dried plant was heated with 15 liters of 80% ethanol (v/v) to 80 °C for 2 h and allowed to continue to 
extract for an additional 10 hours at 20 °C. The extract was filtered through cheesecloth to remove particulates and 
ethanol was removed by rotary evaporation to less than 1 liter of final extract. The aqueous extract was then freeze 
dried from −48 to 20 °C in a glass tray and then homogenized using a mortar and pestle.
Animals. All experiments and procedures were performed in accordance with relevant guidelines and regu-
lations of the Pennington Biomedical Research Center. All animal experiments and procedures were performed 
in accordance to a protocol approved by the Institutional Animal Care and Use Committee (IACUC) of the 
Pennington Biomedical Research Center. Thirty three (33) male C57BL/6J mice at 5 weeks age were ordered from 
Jackson Laboratories, Inc. (Bar Harbor, Maine, USA). After one week quarantine followed by baseline feeding 
of all mice for an additional week on the low fat diet (Research Diets D12450B), mice were randomly divided 
into a low-fat diet group (LFD as negative control, n = 11), high-fat diet group (HFD, Research Diets D12492) as 
positive control, n = 11) and HFD supplemented with UT group (n = 11). UT extract was incorporated into the 
high-fat diet at 0.5% w/w. Mice were singly housed in shoebox cages with corncob bedding in controlled environ-
mental conditions (22 °C), 12 hour light dark cycle with ad libitum access to food and water. Food intake (the dif-
ference of weight administered and leftover plus spillage) and body weight were monitored and recorded weekly.
Body composition measurement. Body composition was determined by nuclear magnetic resonance 
(NMR-Bruker, Newark, DE, USA) as previously shown18. Body fat mass, muscle mass and free fluid were recorded 
at baseline (week 0) and at weeks 6 and 12 of feeding.
Blood chemistry. Fasting (4h) plasma glucose and insulin were determined at baseline and after 6 and 12 
weeks of treatment. Insulin levels were determined by a mouse insulin enzyme linked immunosorbent assay 
(ELISA) kit (Crystal Chem, Downers Grove, IL). Blood glucose was measured using a portable glucometer 
(Milipitas, CA, USA). The intraperitoneal insulin tolerance test (IPITT) and intraperitoneal glucose tolerance test 
(IPGTT) were performed at week 10 and week 12, of feeding respectively as described previously18. For glucose 
tolerance tests, mice were fasted for 6 h prior to injections of 2 g glucose/kg body weight. For insulin tolerance 
tests, mice received 0.5 U of insulin/kg body weight (Humulin; Eli Lilly, Indianapolis, IN). Blood glucose concen-
trations were measured on the nicked tail vein at time 0 (baseline), 15, 30, 60 and 120 min after glucose or insulin 
injections. HOMA-IR was used as a measure of insulin resistance and was calculated from fasting insulin and 
glucose levels. Using the trapezoidal method, the area under curves (AUC) showing the change of blood glucose 
level over the course of IPGT and IPIT were calculated.
Tissue collection and processing. At 18 weeks of age, following 12 weeks of treatment each group was 
divided into basal and insulin-stimulated subgroups. The basal sub group (n = 5), were given an intraperitoneal 
injection of saline after 6 hours fasting while the insulin-stimulated sub group (n = 6) was given insulin at a dose 
of 2 U/kg body weight. After 10 minutes, animals were euthanized by CO2 inhalation followed by cervical disloca-
tion and decapitation. Blood and tissue were snap frozen in liquid nitrogen and stored at −80 °C for later analysis.
Tissue processing and immunoblotting. 50 mg gastrocnemius muscle was dissected and homogenized 
in Buffer A (1% Triton X-100, 20 mmol Tris (pH 75), 2.5 mmol sodium pyrophosphate, 150 mM NaCl, 1 mmol 
EGTA, 1 mmol sodium vanadate, 2 mM beta-glycerophosphate, 1 μg/ml leupeptin, 1 ul/ml aprotinin, 1 ul/ml 
PMSF) using a PRO 200 homogenizer (PRO Scientific, Oxford, CT, USA). Samples were centrifuged (12000 rpm, 
10 min at 4 °C) and protein concentrations of the supernatant determined by the Bio-Rad protein assay kit 
(Bio-Rad laboratories, Inc. Hercules, CA). Supernatants (80 μg) were resolved by SDS-PAGE and subjected to 
standard immunoblotting. Protein abundance was detected with antibodies against, Akt1, Akt2, phospho-Akt 
(ser 473), phospho-Akt (Thr 308), AMPKα 1, AMPKα 2, phospho AMPK (Thr 172) (Millipore, Temecula, CA). 
Other antibodies were PP2A-A, PP2A-B, PP2A-C (Cat No. SC-80665), methyl PP2A-C (Cat No. SC-81603) 
and phospho PP2A Tyr 307 (Cat No. SC-12615) all from Santa Cruz Biotechnology, Santa Cruz, CA). Protein 
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expression levels were normalized by tubulin (Santa Cruz Biotechnology, Santa Cruz, CA). Phosphorylation or 
methylation levels were normalized by the corresponding protein expression. Optical densities of protein bands 
were analyzed using Image J. Data are expressed as the fold difference of the LFD control group.
Cell culture and in vitro assays. C2C12 myoblasts (ATCC; #CRL-1771) were maintained at 37 °C, 95% air 
and 5% CO2 in high glucose DMEM supplemented with 10% FBS serum and antibiotics. For individual experi-
ments, myoblasts were sub-cultured onto 6 well plates, grown to 100% confluence and differentiated into fused 
myotubes for 4 days by switching to media with 2% horse serum. All cells used were within 5 passages. For cell 
culture experiments, the dried extract was solubilized in 100% dimethyl sulfoxide (DMSO) at a concentration 
that was 1000-fold higher than experimental concentrations and then diluted into the cell media. A final con-
centration of 1–10 ug/ml was used to treat cells. Cultures were exposed to FFAs (palmitic acid) conjugated to 1% 
bovine serum albumin (BSA) and constituted to a final concentration 250 μM with or without 5 ug/ml UT extract 
or 10 nM okadaic acid (Millipore, Temecula, CA, USA) for 16 hours. For western blotting, 100 nM insulin was 
added 8 minutes before subsequent collection and analysis. Standard western blotting was performed using 80 μg 
of cell extracts. Specific antibodies used were the same as those shown above. In all cases, western blot results 
were verified in three separate experiments. Data are expressed as the fold difference of the vehicle control. The 
glycogen accumulation assay was performed as described previously10. Results were normalized by protein con-
centration measured by Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA), and glycogen content 
was presented as glucose equivalent per well. To determine glucose uptake, after washing with PBS, cells were 
exposed to 0 or 100 nM insulin in Krebs-Ringer HEPES (KRH) buffer for 15 min followed by an additional incu-
bation for 5 min with 2-deoxy glucose (100 μM, 0.5 μCi). Cells were washed four times with ice-cold KRH buffer, 
lysed in 250 μl of 0.05 N NaOH and then transferred to vials with scintillation cocktail. Radioactivity in the cells 
was measured by liquid scintillation counter.
Ceramide Quantification. Lipids were extracted from 30 mg skeletal muscle or cell lysates correspond-
ing to 300 ug protein and total ceramides quantified by tandemn mass spectrometry (LCMS/MS) as previously 
described5.
PP2A activity. PP2A activity was assayed in lysate corresponding to 300 ug protein processed from cells or 
muscle tissue. Lysis buffer contained 20 mM imidazole-HCl, 2 mM EDTA, 2 mM EGTA, pH 7.0 with 10 mg/mL 
each of aprotinin, leupeptin, pepstatin, 1 mM benzamidine, and 1 mM PMSF. Tissue was homogenized on ice and 
centrifuged at 12,000 rpm for 10 minutes at 4 °C. Cells were sonicated before centrifuging similarly. The superna-
tants were used to assay PP2A phosphatase activity by a standard kit (EMD Millipore, Temecula CA) according 
to the manufacturer’s instructions. The intensity of the color reaction was measured at 650 nm on a Bio-rad 
microplate spectrophotometer.
Statistical analyses. Data are expressed or graphed as mean ± SEM. Statistical significance was determined 
by comparing means by analysis of variance (ANOVA). Significant differences observed were followed up using 
the Fisher’s least significant difference (LSD) test. All tests used P < 0.05 as the level of statistical significance.
Results
Supplementation of HFD with Urtica dioica L. does not alter food intake, body weight or body 
composition. At baseline at six weeks of age, body weights were not statistically different in the three groups. 
At week 12 the weights had increased by 27.1% in the LFD group, 63.6% in the HFD and 58.4% in the HFD + UT 
group (Table 1). The HFD and HFD + UT were not significantly different (p = ns, Table 1) but, both were 
LFD HFD HFD/UT
Food intake per 
day (grams) 2.56 ± 0.81 2.23 ± 0.49 2.26 ± 0.61
Body weight (grams)
 Week 0 22.02 ± 0.45 21.82 ± 0.46 22.08 ± 0.18
 Week 6 25.68 ± 0.44 30.40 ± 0.70 29.63 ± 0.88
 Week 12 27.99 ± 0.60 35.68 ± 1.15 34.98 ± 1.11
Body composition (% Fat)
 Week 0 14.96 ± 0.50 15.56 ± 1.06 15.43 ± 0.89
 Week 6 17.33 ± 0.99 25.03 ± 1.48 27.08 ± 2.18
 Week 12 16.23 ± 1.14 28.38 ± 1.14 29.58 ± 2.02
Body composition (% Muscle)
 Week 0 70.63 ± 0.15 69.91 ± 0.09 70.35 ± 0.23
 Week 6 69.64 ± 0.25 63.07 ± 0.21 62.05 ± 0.13
 Week 12 69.58 ± 0.21 60.90 ± 0.31 59.54 ± 0.20
 Circulating FFAs 
(week 12) (mmol/l) 0.39 ± 0.1 0.45 ± 0.03 0.44 ± 0.09
Table 1.  Food intake, body weight, body composition and circulating FFAs.
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significantly different from LFD (LFD vs HFD, P < 0.01; LFD vs HFD + UT, P < 0.01). Daily food consumption 
was higher in LFD group but was not different between HFD and HFD + UT groups (Table 1). As expected, body 
composition was similar in the three groups at baseline. After 12 weeks feeding, there was a 12.7% increase in fat 
mass with LFD, 82.4% increased for the HFD, and 91.7% in the HFD + UT group. Notably, fat mass was not statis-
tically different between HFD and HFD + UT groups. After 12 weeks of treatment, the decrease in percent muscle 
was 1.49%, for the LFD group, 14.8% for the HFD and a 15.4% decrease was observed in the HFD + UT group. 
There were no statistical differences in percent muscle between HFD and HFD + UT groups (Table. 1). Free fluid 
mass was not different between the three groups and did not change over the 12 weeks (data not shown).
Supplementation of HFD with Urtica dioica L. enhances glucose disposal and insulin signaling 
in vivo. Fasting plasma glucose and insulin were not different between the three groups at baseline but were 
significantly increased in the HFD group by week 12 (Fig. 1a,b). Insulin resistance (HOMA-IR) was increased in 
the HFD (Fig. 1c). Supplementation of the HFD with UT significantly lowered fasting glucose and insulin and 
improved insulin resistance as assessed by HOMA-IR (HFD vs HFD + UT, P < 0.01; Fig. 1a–c). In a glucose tol-
erance test, blood glucose levels for the HFD + UT group were significantly lower than those of the HFD group at 
the 60, 90 and 120 minute intervals (P < 0.01;Fig. 1d). However, both the HFD and HFD + UT groups had signif-
icantly higher glucose at these time intervals when compared to the LFD group. In an insulin tolerance test, blood 
glucose levels in the HFD + UT group were significantly lower than those of the HFD only at the 120 minute 
interval (P < 0.01) and were not different from LFD group at all other time intervals (Fig. 1e). The rate of decline 
of glucose between baseline and 60 minutes after insulin injection was 2.2, 1.3 and 1.54% per minute for LFD, 
HFD and HFD/UT respectively and was not statistically different between the HFD and the HFD/UT groups. The 
area under curves (AUC) for glucose tolerance test was not different between the HFD and the HFD/UT groups. 
However the AUC for insulin tolerance test curve was significantly lower in the HFD/UT group compared to the 
HFD group (Table 2).
To assess potential direct effects on skeletal muscle, insulin signaling was examined in gastrocnemius muscle 
from these mice. As shown in Fig. 2, HFD feeding was accompanied by a loss of insulin stimulated Akt serine 
and threonine phosphorylation. Supplementation of the HFD with UT significantly enhanced insulin stimulated 
Akt serine and threonine phosphorylation (P < 0.01; Fig. 2). There were no differences in Akt 1 and Akt 2 protein 
expression levels among the three groups. UT supplementation had no effect on IRS, insulin receptor protein 
expression, or P13K and AMPK protein expression and activity (data not shown).
Figure 1. UT extract significantly enhanced plasma glucose homeostasis. Male 6 week old C57BL/6J mice 
were fed the respective experimental diets for 12 weeks. After a four hour fast at weeks 0, 6 and 12, (a) blood 
glucose was determined using a portable glucometer and (b) insulin was determined by an ultrasensitive mouse 
insulin enzyme linked immunosorbent assay (ELISA) kit. (c) HOMA-IR at week 12 was calculated from fasting 
insulin and glucose levels. (d) The Intraperitoneal glucose tolerance test (IPGT) was performed at week 12. 
Mice were fasted for 4 h prior to injections with 2 g glucose/kg body weight. Blood glucose concentrations were 
measured on the nicked tail vein at the indicated time frames after glucose injection. (e) The intraperitoneal 
insulin tolerance test (IPIT) was performed at week 10. Mice were fasted for 4 h prior to injections with 0.5 U 
of insulin/kg body weight. Blood glucose concentrations were measured on the nicked tail vein at the indicated 
time frames after glucose injection. Data are mean ± SEM (n = 11). #denotes significant difference between 
HFD and HFD + UT (P < 0.05).
www.nature.com/scientificreports/
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Supplementation of Urtica dioica L. to FFA treated C2C12 myotubes reduces the effects of FFA 
on insulin signaling, glucose uptake and glycogen synthesis. As expected, exposure of myotubes 
to FFAs induced a decrease in Akt phosphorylation and also decreased insulin induced glycogen synthesis. 
Co-incubation with FFAs and 5 ug/ml UT or okadaic acid attenuated the ability of FFAs to induce Akt dephos-
phorylation and reduce glycogen synthesis (Fig. 3a lane 4 vs lane 6 and 10 and Fig. 3b). Incubation with UT 
only or okadaic acid only enhanced Akt phosphorylation and increased glycogen accumulation compared to the 
vehicle only treatment (P < 0.05; Fig. 3a lane 2 vs lane 8 and Fig. 3b). Co-incubation with FFAs and 5 ug/ml UT or 
okadaic acid enhanced glucose uptake (Fig. 3c) compared to vehicle only treatment.
Ceramide levels and PP2A protein activity and expression in skeletal muscle. As expected, skel-
etal muscle of the HFD group accumulated ceramides and had significantly increased level of PP2A activity 
compared to the LFD group. UT supplementation did not lower ceramides significantly (Fig. 4a) but lowered 
PP2A activity significantly compared to the HFD (P < 0.01; Fig. 4b). Protein expression of PP2A subunits A 
and B between the three groups was not different (data not shown). Expression of PP2A subunit C was also not 
different but phosphorylation level of PP2A-C on Tyr307, an indicator of PP2A inactivation, was lowered in the 
HFD group when compared to LFD. UT supplementation enhanced this phosphorylation significantly compared 
to the HFD group (P < 0.01; Fig. 4c). Methylation of PP2A-C on Leu309, also an indicator of PP2A catalytic activ-
ity, was higher in the HFD group compared to LFD. UT supplementation in the HFD significantly lowered this 
methylation (P < 0.01; Fig. 4c).
Ceramide levels and PP2A protein activity and expression in cultured myotube. As expected, 
exposure of myotubes to FFAs increased ceramide levels by more than one fold (Fig. 5a) and enhanced PP2A 
activity (Fig. 5b). Co-incubation with FFAs and UT or okadaic acid had no effect on ceramide accumulation 
but lowered PP2A activity compared to the FFA treatment only (P < 0.01; Fig. 5a,b). FFAs and UT had no effect 
on protein expression of PP2A subunits A, B and C (Fig. 5c,d). However, FFAs significantly lowered PP2A-C 
phosphorylation on Tyr307 and enhanced methylation on Leu309 (P < 0.01; Fig. 5d lanes 1 and 2 vs lanes 3 and 









23,878 ± 967 34,258 ± 1105 27,440 ± 589*
Table 2.  Values of Area under the curve. *significantly different with HFD.
Figure 2. UT extract enhances insulin signaling in skeletal muscle tissue. Male C57BL/6J mice were fed the 
experimental diets for 12 weeks. Ten minutes prior to sacrifice, mice were injected with 2 U/Kg body weight 
insulin or saline. Protein homogenates from the gastrocnemius muscle were separated by SDS-PAGE and 
analyzed by immune blot analysis. Representative blots for Akt phosphorylation and expression are shown. Fold 
change relative to LFD alone for each Akt phosphorylation was calculated and mean ± SEM graphed (n = 11). 
#denotes significant difference between HFD and HFD + UT (P < 0.05).
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compared to FFA treatment alone (P < 0.01; Fig. 5d; lanes 3 and 4 vs lanes 5 and 6). Incubation with UT only 
enhanced PP2A-C Tyr307phosphorylation compared to the vehicle only treatment (P < 0.01; Fig. 5d; lanes 1 and 
2 vs. lanes 7 and 8).
Discussion
In this study, we report the effects of a UT extract on plasma glucose homeostasis and insulin signaling in skeletal 
muscle tissues from mice fed a high-fat diet. Consistent with prior reports in rats10–13, we show that supplement-
ing a high fat diet with UT enhances glucose homeostasis. Several studies have demonstrated that excess dietary 
lipids results in accumulation of lipid metabolites particularly ceramides that impair insulin signaling in insulin 
sensitive tissues5–7,19–21. To date, there are no reported studies on the effects of UT on skeletal muscle insulin sen-
sitivity. We show that UT supplementation enhances skeletal muscle insulin sensitivity despite the accumulation 
of ceramides. Furthermore, UT attenuated FFA induced insulin resistance in myotubes by enhancing Akt phos-
phorylation despite the accumulation of ceramides. We further show that the enhanced Akt phosphorylation is 
accompanied with a reduction in HFD or FFA induced hyperactivity of PP2A, the phosphatase that is activated 
by ceramides and is responsible for dephosphorylating Akt.
The connection between insulin resistance and obesity is well established. Obesity leads to elevated levels 
of circulating FFAs that contribute to insulin resistance by promoting excessive deposition lipid metabolites in 
tissues not suited for fat storage such as skeletal muscle5–7,18–20. Here in we report on the effects of UT on glucose 
homeostasis and insulin signaling in skeletal muscle of a robust pre-diabetes model; high fat fed C57BL/6J mice. 
These mice developed mild to moderate hyperglycemia, post- glucose load hyperglycemia, fasting hyperinsuline-
mia, and a diminished insulin response after 12 weeks feeding. Supplementation of the HFD with UT improved 
glucose homeostasis and insulin sensitivity as assessed by, IPIT and HOMA-IR without affecting food intake, 
body weight or body composition (Tables 1 and 2; Fig. 1).
We evaluated the effects of UT in skeletal muscle because it is the site of majority of insulin-stimulated glucose 
disposal and insulin resistance in skeletal muscle can be evident decades before β -cell failure and overt hyperg-
lycemia22,23. Supplementation of the HFD with UT abated insulin resistance as evidenced by enhanced levels of 
Akt phosphorylation on Ser473 and Thr308 (Fig. 2). Akt is a serine/threonine kinase that mediates many effects of 
insulin including glucose uptake and metabolism. Akt activation depends on regulatory mechanisms that require 
dual phosphorylation on Ser473 and Thr308 by PDK1 and the TORC2 complex respectively and translocation to the 
Figure 3. UT extract enhances insulin signaling and glucose uptake in skeletal muscle cells. Fully 
differentiated C2C12 myotubes were incubated with palmitate (250 uM) with or without UT (5 ug/ml) or 10 nM 
okadaic acid (OK) for 16 hours and (a) myotubes were stimulated with vehicle or 100 nM insulin for 8 minutes. 
Cell lysates were separated by SDS-PAGE and analyzed by immune blot analysis for Akt serine and threonine 
phosphorylation and Akt protein expression. The bar chart represents quantification of band density by image J 
software. (b) A second set of cells was used to determine glycogen accumulation with use of glycogen hydrolysis 
followed by glucose determination in both basal and insulin-stimulated states. Results represent an experiment 
independently repeated three times on different batches of myotubes. (c) A third set of cells was used to 
determine glucose uptake in both basal and insulin stimulated states by determining radioactivity after uptake 
of 2-deoxy glucose. *denotes significant difference with FFA only treatment (P < 0.05). #denotes significant 
difference with the control treatment (P < 0.05).
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plasma membrane15,16,20,21. By moderating these effects on Akt, UT enhanced insulin sensitivity in skeletal muscle. 
The in vitro data complemented the in vivo data by showing that UT attenuated the inhibitory effects of FFAs on 
Akt phosphorylation at Ser473 and Thr308 and insulin stimulated glycogen synthesis; an essential downstream 
function that results from the phosphorylation and inactivation of GSK-3 by Akt. Activated GSK-3 reduces gly-
cogen synthesis and plays a dominant role in inducing skeletal muscle insulin resistance24. UT enhanced glucose 
uptake in both FFA treated and control cells. We included a treatment with okadaic acid (OK) a naturally occur-
ring polyether that enhances Akt phosphorylation by inhibiting PP2A. UT effects were comparable to those of 
OK in attenuating the ability of FFAs to induce insulin resistance in skeletal muscle cells (Fig. 3).
Among lipid metabolites that accumulate with high fat diets, ceramides have been shown to be the most active 
in negatively regulating insulin signaling by blocking the activation of Akt without affecting upstream signaling 
events5–7,19–21. Akt is dependent on stimulatory signals from the insulin receptor for activation but is simultane-
ously under negative control by phosphatases particularly PP2A15–17,21,25. Studies in insulin responsive cells, have 
implicated hyperactivity of PP2A in the pathogenesis of Akt dephosphorylation, leading to attenuation of glucose 
transport stimulation17,20. PP2A is a serine/threonine phosphatase that leaves Akt dephosphorylated and unable 
to translocate to the plasma membrane. In contrast to other lipids, ceramides have been shown to be specific acti-
vators of PP2A25. Besides activating PP2A, ceramides that accumulate in caveolin-enriched domains of the cell 
membrane also interfere with PKCzeta catalyzed phosphorylation of Akt thus preventing it from participating 
in downstream insulin receptor signaling7. Insulin inhibits PP2A activity but this effect is diminished in diabetic 
models25. Our data shows that UT attenuated the ability of accumulated ceramides to induce PP2A hyperactivity 
without lowering ceramide levels in muscle tissue and C2C12 myotubes (Figs 4 and 5). We concluded that inhi-
bition of PP2A activity in skeletal muscle by UT plays a role in the significant increase in Akt phosphorylation 
observed despite the increased levels of ceramides.
The major finding and one that requires a mechanism is UT how reduces PP2A activity. We therefore eval-
uated UT effects on PP2A expression and posttranslational modification. PP2A is a heterotrimeric complex 
Figure 4. UT extract attenuates HFD induced hyperactivity of PP2A and enhances Akt phosphorylation 
in skeletal muscle. Male C57BL/6J mice were fed were fed the experimental diets for 12 weeks. After sacrifice 
(a) 30 mg of gastrocnemius muscle was extracted for lipids by the Folch partition and ceramide quantities 
determined by tandemn mass spectrometry (LC/MS/MS). (b) 30 mg muscle was homogenized and lysates 
used to determine phosphatase PP2A activity by a standard kit (EMD Millipore, Temecula CA). (c) Protein 
homogenates from 20 mg gastrocnemius muscle were separated by SDS-PAGE and analyzed by immune 
blot analysis. Representative blots for PP2A- C protein expression, PP2A-C tyrosine phosphorylation and 
PP2A-C leucine methylation are shown. Fold change relative to LFD alone for each protein was calculated and 
mean ± SEM graphed (n = 11). #denotes significant difference with HFD (P < 0.05).
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comprised of a structural or scaffolding subunit A, a regulatory subunit B, and a catalytic subunit C17,26,27. It con-
trols the phosphorylation of a wide range of substrates but gains specificity through the targeting regulatory sub-
unit B21,25. Phosphorylation of the catalytic subunit at Tyr307 results in substantial reduction of activity17,21,25. The 
catalytic subunit is also subject to methyl esterification of its C terminus on Leu-309. This methylation activates 
the enzyme. Inhibiting methylation contributes to a decrease in activity25,27. We show that the enhanced PP2A 
activity in HFD mice muscle resulted from increased Leu309 methylation and decreased Tyr307 phosphorylation 
of the catalytic subunit. UT supplementation reduced Leu309 methylation and increased Tyr307 phosphorylation 
thus decreasing overall activity of the enzyme (Fig. 4). In C2C12 myotubes, UT attenuated FFA induced PP2A 
methylation resulting in lower levels of enzyme activity without affecting protein expression (Fig. 5). Okadaic 
acid, a known PP2A inhibitor, decreased FFA induced PP2A hyperactivity by more than 50% while UT decreased 
it by about 32% resulting in an increased relative amount of phosphorylated Akt. However, it is difficult to com-
pare activity because the bioactive components of UT extract are unknown. Our data suggests that a contributing 
mechanism, by which UT enhances insulin sensitivity in skeletal muscle in the presence of excess dietary lipids, 
is modulation of PP2A activity.
A limitation of our study is that we have not elucidated the bioactive components of UT. Identification of the 
active components of UT will be an important next step for determining its potential as a metabolically beneficial 
botanical supplement for obesity induced insulin resistance. Since stinging nettle has a history of human use as a 
food, the effects of its components are unlikely to pose toxicity issues. This was corroborated in this study. Based 
on work done using the whole extract we conclude that UT components attenuate obesity induced insulin resist-
ance through mechanisms that enhance Akt phosphorylation and its downstream effects without affecting food 
intake, body weight or body composition.
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